Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Brachytherapy in Treating Patients With Recurrent Malignant Glioma

Study:

Phase I Brachytherapy Dose Escalating Study Using the Proxima Therapeutics, Inc. GliaSite RTS in Patients With Recurrent Malignant Gliomas

Rationale:

Brachytherapy uses radioactive material to kill cancer cells remaining after surgery.

Purpose:

Phase I trial to study the effectiveness of brachytherapy in treating patients who have recurrent malignant glioma.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Brain and Central Nervous System Tumors Procedure: adjuvant therapy
Radiation: iodine I 125
Phase 1

Verified by National Cancer Institute (NCI) April, 2003

Sponsored by: National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00045474

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Larry Kleinberg, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site